The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
Official Title: An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis
Study ID: NCT01290029
Brief Summary: The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
Detailed Description:
Minimum Age: 28 Days
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
Research Site, Louisville, Kentucky, United States
Research Site, Kansas City, Missouri, United States
Research Site, Heidelberg, , Germany
Research Site, Bristol, , United Kingdom
Research Site, Glasgow, , United Kingdom
Research Site, Leeds, , United Kingdom
Research Site, Manchester, , United Kingdom
Research Site, Nottingham, , United Kingdom
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR